|
Frost & Sullivan's 2006 Technology Innovation Award Goes
To Aethlon Medical
Company's Medical Defense Fills Void in the War Against Bio-Terrorism
SAN DIEGO----Feb. 15, 2006--Aethlon Medical, Inc. (OTCBB:AEMD ), a pioneer
in developing therapeutic devices for infectious disease, announced today
that it is the recipient of the 2006 Technology Innovation Award in the
field of Biodefense Technologies for Homeland Security. The International
Award is presented by Frost & Sullivan, a global market trend research
organization. It acknowledges Aethlon's development of the inventive
Hemopurifier(TM) technology, which can be deployed as the first line of
defense against a broad spectrum of drug and vaccine resistant pathogens.
The Technology Innovation Award is presented each year to a company that has
carried out new research that has resulted in innovation(s) that have or are
expected to bring significant contributions to the industry in terms of
adoption, change, and competitive posture. The Award is based on over four
hundred hours of market research, and recognizes the quality and depth of a
company's research and development program as well as the vision and risk
taking that enabled it to undertake such an endeavor.
James A. Joyce, Aethlon's Chairman & CEO, stated, "We are honored to receive
this recognition, and appreciate that analysts at Frost & Sullivan recognize
the importance of treatment countermeasures whose mechanism of action offers
the potential to treat a broad spectrum of bio-terror agents." "These same
treatment attributes will also be crucial in combating emerging pandemic
threats such as the H5N1 strain of Avian Flu," concluded Joyce.
According to Frost & Sullivan, there has been a huge lapse in the
development of effective drug or vaccine countermeasures for diseases caused
due to biological warfare and emerging pandemic issues. Currently, many
biotechnology companies are working on identifying methods to innovate
technologies to deliver solutions that address this urgent requirement, and
at the forefront of this trend is Aethlon Medical. The Company has
established its competence in developing viral filtration technologies that
can clear drug- and vaccine-resistant pathogens from blood circulation. The
technology can also be deployed against currently untreatable pathogens
released through bioterrorism.
"This technology can filter diverse pathogens including Smallpox, Ebola,
Marburg and Anthrax toxins, and is based on the fundamental principles of
affinity chromatography and hemodialysis that enable the identification,
isolation and removal of the viruses prior to cell and organ infection,"
says Frost & Sullivan research analyst Haritha Ramachandran. "The technology
can also identify and eliminate genetically modified envelope viruses and
can be targeted for use against chronic conditions such as HIV and
Hepatitis-C."
Frost & Sullivan reports that the Hemopurifier(TM) is based on a two-stage
process to reduce toxins in the body. The first stage involves the
separation of viruses and viral toxins from blood using established
techniques, similar to those employed in blood dialysis. The second part
involves the immobilization of affinity agents that bind tightly to
glycoproteins that reside on the envelope of viruses. The Hemopurifier(TM)
concept may be the only technology that effectively rids a virus from the
blood/medium where it has been detected. Due to this unique feature, the
Hemopurifier appears best positioned to treat patients when conventional
drugs or vaccines are not effective or are not readily available.
"With several key patents already filed and several more pending, Aethlon
Medical has successfully established a robust research and development
program," notes Haritha. "Through a productive R&D effort, promising
products, and strategic alliances, Aethlon Medical is poised to leave an
indelible mark in the field."
About Aethlon Medical
Aethlon Medical is developing the first medical device to treat infectious
disease. The device, known as the Hemopurifier(TM), is a broad-spectrum
treatment countermeasure against drug and vaccine resistant bioweapons,
naturally evolving pandemic threats such as H5N1 Avian Flu, and chronic
infectious disease targets including Hepatitis-C (HCV) and the Human
Immunodeficiency Virus (HIV). More information on Aethlon Medical and the
Hemopurifier(TM) technology can be found at
www.aethlonmedical.com.
About Frost & Sullivan
Frost & Sullivan, a global growth consulting company, has been partnering
with clients to support the development of innovative strategies for more
than 40 years. The company's industry expertise integrates growth
consulting, growth partnership services, and corporate management training
to identify and develop opportunities. Frost & Sullivan serves an extensive
clientele that includes Global 1000 companies, emerging companies, and the
investment community by providing comprehensive industry coverage that
reflects a unique global perspective and combines ongoing analysis of
markets, technologies, econometrics, and demographics. For more information,
visit www.frost.com.
Certain of the statements herein may be forward-looking and involve risks
and uncertainties. Such forward-looking statements involve assumptions,
known and unknown risks, uncertainties and other factors which may cause the
actual results, performance or achievements of Aethlon Medical, Inc to be
materially different from any future results, performance, or achievements
expressed or implied by the forward-looking statements. Such potential risks
and uncertainties include, without limitation, the Company's ability to
raise capital when needed, the Company's ability to complete the development
of its planned products, the ability of the Company to obtain FDA and other
regulatory approvals permitting the sale of its products, the Company's
ability to manufacture its products and provide its services, the impact of
government regulations, patent protection on the Company's proprietary
technology, product liability exposure, uncertainty of market acceptance,
competition, technological change, and other risk factors. In such
instances, actual results could differ materially as a result of a variety
of factors, including the risks associated with the effect of changing
economic conditions and other risk factors detailed in the Company's
Securities and Exchange Commission filings.
Contact:
Aethlon Medical, Inc.
Jeff Richardson, 858.459.7800 x302
jrichardson@aethlonmedical.com
James A. Joyce, 858.459.7800 x301
jj@aethlonmedical.com
--------------------------------------------------------------------------------
Source: Aethlon Medical, Inc.
|
|
